Showing: 1 - 2 of 2 RESULTS

Summa Equity Acquires Sengenics to Advance Precision Medicine Through Proteomics

Summa Equity, the purpose-driven private equity firm that invests to solve global challenges, has acquired a majority stake in Sengenics, a functional proteomics company with a proprietary technology called KREX that enables researchers to vastly improve the understanding of the human proteome and immune system. Proteomics, i.e. the large-scale study of proteins, is one of the most important areas for gaining insights into human biology and disease, as protein expressions, structures and functions are critical in reflecting states of health.

Sengenics was first founded in 2008 and went on to commercialise the KREX technology that was originally developed from a joint collaboration between the University of Cambridge and the University of Oxford. The company’s patented KREX technology enables researchers to address both the function and folding structure of proteins using one technology that allows for large numbers of proteins to be studied simultaneously, with high sensitivity and specificity. The combination of these capabilities makes KREX unique. The technology is relevant for a broad range of applications in research and throughout the value chain for drugs, vaccines and diagnostics. Sengenics is currently mainly focused on autoantibody detection for applications in autoimmune diseases, oncology and infectious diseases, including COVID-19. The company recently launched a unique high-throughput, multi-antigen, multi-domain and fully quantitative COVID-19 test, leveraging the KREX technology.

Sengenics has grown rapidly in recent years and established customer relationships with top global pharmaceutical companies, and leading research and academic institutions around the world. The company currently has commercial partnerships with 9 out of the top 10 pharmaceutical companies to co-develop complementary and companion diagnostic tests for autoimmune and cancer immunotherapy drugs. Sengenics is based in Europe and South-East Asia.

“Sengenics’ proprietary technology unlocks tremendous potential for researchers around the world to further their understanding of biology and disease,” says Tommi Unkuri, Partner at Summa Equity. “We are proud to partner with the company and support its journey, as it looks to expand its position in the market and grow its business. We look forward to supporting the Sengenics team in our shared ambition to invest to drive product development, global expansion and accelerated adoption.”

Summa Equity invests in companies that address global challenges, while managing environmental, social, and governance (ESG) factors, with the aim of increasing returns and reducing risk. It was the first company to align its investments with the UN Sustainable Development Goals. The investment in Sengenics is aligned with the firm’s Changing Demographics theme and supports the SDG Target #3: “Ensure healthy lives and promote well-being for all at all ages”, by enabling improved diagnosis, treatment and patient outcomes across a number of disease areas.

“We are excited to welcome Summa Equity as a major strategic investor and shareholder in Sengenics. Their extensive capabilities and alignment with our vision of changing the future of medicine through immune-proteomics is a very strong strategic fit. Summa also has a great deal of relevant knowledge and experience to be a value-added owner for us given its ownership of Olink Proteomics. This

Vitalyc Medspa Acquires Unit Skin Studio

The Dallas Medspa Offers Non-Invasive Solutions for the FACE, BODY, & SKIN

Vitalyc Medspa, located at 6915 Preston Road in Dallas, has acquired Unit Skin Studio. The acquisition will absorb the Unit Skin Studio’s staff and clients into Vitalyc‘s Flagship location in University Park. Vitalyc offers solutions to help people age on their own terms using the latest non-invasive aesthetic treatments for both women and men.

Founder & CEO Amir Mortazavi created Vitalyc to provide both men and women with a direct path to anti-aging and has plans to open 25 locations in the next 5 years. While most of those will be new builds, Mortazavi affirms there are plenty of opportunities to acquire well-established business-like Unit Skin Studio and either rebrand or fold them into existing Vitalyc locations. Vitalyc blends the best treatment technology with the top aesthetic professionals to produce lasting results creating an UBER-like experience for consumers. Vitalyc uses app-based technology allowing clients to schedule appointments, monitor treatment progress, and check out using a contactless mobile experience.

“Our goal from the beginning was to provide our clients with an elevated experience which includes the latest technology and a dedicated team of experts,” says Unit Skin Studio Founder Lindsey Pinyero. “We are proud to transition our Unit family to Vitalyc to continue on their aesthetic journey and defy aging. Our passion has always been focused on service, experience, and results, Vitalyc delivers on all levels making the transition for our team simple!”

“We are committed to being good stewards of the businesses people put blood, sweat, and tears into,” says Mortazavi. “We believe through our technology, customer experience, and clinical excellence we can carry the torch for decades to come and are always looking for opportunities in Texas’s major suburban markets.”

The clinical team lead by facial plastic surgeon Demetri Arnaoutakis & Richard Moleno, took two years to curate the best equipment to treat conditions including unwanted fat, acne, enlarged pores, wrinkles, sagging skin, poor muscle definition, sun damage, volume loss, hormone imbalance, and dehydration.

“Our mission is restore confidence and defy aging,” says Mortazavi, whose state of the art treatment center boasts eight specialized rooms and a welcoming atmosphere whether you are a millennial or baby boomer.

To book your appointment, visit www.vitalyc.com or call (972) 994-9700.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005215/en/

Contacts

Allie Lesiuk
allie@theprcollaborative.com
817-733-3766

Source Article